Does Cosentyx Affect Vaccine Response Strength?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. Clinical data shows it weakens antibody responses to certain vaccines, particularly non-live ones like influenza and pneumococcal.
In a phase 3b trial (OCTAVE), patients on secukinumab produced lower geometric mean antibody titers against influenza strains compared to placebo after vaccination. Seroprotection rates dropped by 10-20% for H1N1 and H3N2.[1] For pneumococcal vaccine (PCV13), seroconversion was reduced by about 15% across serotypes.[2]
Live vaccines are contraindicated due to infection risk from immunosuppression.[3]
How Long Do Vaccine Responses Last on Cosentyx?
Antibody levels decline faster post-vaccination. In studies, secukinumab patients had waning titers by 24 weeks, versus sustained protection in controls.[1] Annual flu shots remain recommended, but efficacy may be suboptimal—patients should vaccinate before starting therapy if possible.
Which Vaccines Work Best with Cosentyx?
- Stronger responses: Tetanus toxoid and HPV vaccines show minimal impact; seroprotection rates exceed 90%.[2]
- Weaker responses: Influenza (10-25% lower), pneumococcal (15% lower), hepatitis B (variable, often reduced).[4]
- Avoid: Live vaccines (e.g., MMR, varicella, oral polio, yellow fever).[3]
COVID-19 mRNA vaccines elicit robust responses, but titers are 20-30% lower than in non-immunosuppressed groups.[5]
Timing Vaccines Around Cosentyx Doses
Vaccinate 4-6 weeks before first Cosentyx dose for peak response. Post-treatment, responses improve within 12 weeks of stopping, but consult prescribers—holding doses isn't routine.[3] No need to pause for inactivated vaccines during therapy.
Patient Risks and Real-World Reports
Higher breakthrough infection rates occur with weaker vaccine responses, especially in older patients or those with comorbidities. FDA label warns of reduced immunogenicity; monitor titers if high-risk.[3] Forums like PatientsLikeMe report flu-like illnesses post-vaccination despite Cosentyx.
Cosentyx vs. Other Biologics for Vaccines
| Drug | Influenza Response Impact | Pneumococcal Impact |
|------|---------------------------|---------------------|
| Cosentyx | Mild-moderate reduction | Moderate reduction |
| Humira (adalimumab) | Moderate-severe | Severe |
| Stelara (ustekinumab) | Minimal | Minimal |
| Tremfya (guselkumab) | Mild | Mild[6] |
IL-17 inhibitors like Cosentyx preserve more T-cell function than TNF blockers, leading to relatively better vaccine responses.
[1] PubMed: Secukinumab influenza vaccine trial
[2] PubMed: Pneumococcal response
[3] Cosentyx Prescribing Information (Novartis)
[4] EULAR recommendations on vaccination
[5] PubMed: COVID-19 vaccines in IL-17 inhibitors
[6] Rheumatology journal comparison